PhageLab

PhageLab is a biotech company founded in 2009, headquartered in Chile. With the slogan "A biotech company creating tailor-made solutions to global bacterial challenges. Science works and we can prove it," PhageLab has carved a niche for itself in the Biotechnology, Enterprise Software, and Pharmaceutical industries. Their unique approach involves partnering with poultry and livestock producers to develop custom antibacterial solutions, targeting specific bacterial pathogens through an AI-powered streamlined sample protocol. Their commitment to long-term farm health is evident in their provision of fast, precise diagnosis and solution development. This innovative company has recently secured an impressive $11.00M Series A investment from notable investors including Collaborative Fund, WaterLemon Ventures, Nazca Ventures, and Kevin Efrusy on 23 January 2024. PhageLab's competitive edge is further reinforced by its access to one of the largest global bacteriophage repositories and unmatched data-gathering capabilities, placing them at the forefront of science and technology. Notably, the company holds trademarks in Chile, Brazil, Peru, Mexico, Europe, the United Kingdom, Argentina, and the United States, reflecting its global ambitions and reach. With offices in Brazil and Spain, PhageLab is keen on demonstrating their commitment to the principles of One Health, as they continue to make waves in the biotech industry.